bioAffinity Technologies’ (BIAF) “Hold” Rating Reaffirmed at Maxim Group

bioAffinity Technologies (NASDAQ:BIAF)‘s stock had its “hold” rating reissued by equities research analysts at Maxim Group in a report issued on Tuesday,Benzinga reports.

bioAffinity Technologies Price Performance

Shares of NASDAQ BIAF opened at $0.89 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.02 and a debt-to-equity ratio of 0.18. bioAffinity Technologies has a fifty-two week low of $0.24 and a fifty-two week high of $3.16. The business has a 50 day moving average price of $0.58 and a two-hundred day moving average price of $1.06. The firm has a market cap of $13.87 million, a PE ratio of -1.09 and a beta of 3.12.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07). The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $2.42 million. bioAffinity Technologies had a negative return on equity of 205.09% and a negative net margin of 91.22%.

Institutional Trading of bioAffinity Technologies

A hedge fund recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC raised its stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.